{"classes":[{"categories":[{"measurements":[{"comment":"Upper limit of 95% CI was not estimable due to low number of responders with events.","groupId":"OG000","lowerLimit":"15.9","upperLimit":"NA","value":"24.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"}],"units":"Participants"}],"description":"DOR is defined as the time from the date of first documentation of PR or better to the date of the first documented PD among participants who responded to the treatment.","dispersionType":"95% Confidence Interval","groups":[{"description":"Ixazomib, 4 mg, capsules, orally, on Days 1, 8 and 15 of each 28-day cycle along with daratumumab, 16 mg/kg, intravenously (IV), on Days 1, 8, 15 and 22 of Cycles 1 and 2, on Days 1 and 15 (every 2 weeks) for Cycles 3 to 6 and on Day 1 (every 4 weeks) for Cycle 7 and beyond along with dexamethasone, 20 mg, tablets, orally on Days 1, 2, 8, 9, 15, 16, 22 and 23 of each 28-day cycle until progressive disease (PD), unacceptable toxicity, or withdrawal of consent, or up to 5 years.","id":"OG000","title":"Ixazomib 4 mg + Daratumumab 16 mg/kg + Dexamethasone 20 mg"}],"paramType":"MEDIAN","populationDescription":"Response-evaluable population included participants who received at least 1 dose of ixazomib, had measurable disease during the screening period, and had at least 1 postbaseline disease assessment. The data is reported for the responders.","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Duration of Response (DOR)","type":"SECONDARY","unitOfMeasure":"months"}